α
AlphaScala
StocksSignalsNEWAlpha ScoreBrokers
Sign InGet Started
α
AlphaScala

Professional trading analysis with publicly tracked portfolios on TipRanks. Real trades, real data.

Markets

ForexStocksCryptoCommodities

Tools

Stock ResearchMarket SignalsAlpha ScoreHedge Funds 13FInsider BuysAgentic TradingAI Broker MatcherBroker ReviewsPortfoliosFree IndicatorsBlogLearn TradingTrading Q&A

Account

Sign InDashboardNewsletterContact UsAdvertise

Legal

AboutEditorial PolicyCorrectionsTerms of ServicePrivacy PolicyRisk Disclaimer

Risk Warning: AlphaScala provides educational content only and is not a financial advisor. Trading and investing involves substantial risk of loss and is not suitable for all investors. Past performance does not guarantee future results. You should consult a licensed financial advisor before making investment decisions. See our full risk disclaimer.

For AI AgentsAlphaScala is agent-ready —skill.md·llms.txt
© 2026 ROGA AI LIMITED · Registered in Gibraltar · Unit G02, Eurocity, Europort Avenue, Gibraltar GX11 1AAAlphaScala — Built with data, not hype.
All Stocks/Healthcare/MEDP

Medpace Holdings, Inc.

MEDP
HealthcareDiagnostics & Research Website
Alpha Score
52
Weak
Signal SnapshotMarket signals →
Alpha Score
52 · Weak
Alpha Score of 52 reflects moderate overall profile with strong momentum, poor value, strong quality. B...
Updated Apr 15
Insiders
No recent signal
No recent open-market insider buying or selling is in the current rollup.
Form 4
13F Holder
D.E. Shaw
$296.68M reported position; latest action: new.
David Shaw
Latest Filing
No filing digest
Recent 10-K, 10-Q, and 8-K summaries will appear here when available.
SEC digest
Price ChartPowered by TradingView
Ask about MEDPAI research agent
Alpha Score BreakdownHow it works →

Alpha Score of 52 reflects moderate overall profile with strong momentum, poor value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Momentum
85
Strong
Value
0
Poor
Quality
83
Strong
Sentiment
—
no data
Key StatisticsUpdated Apr 15
P/E Ratio
121.53
Forward P/E
—
PEG Ratio
—
EPS (TTM)
4.26
Dividend Yield
—
Beta
1.40
Revenue (TTM)
—
Net Margin
17.83%
ROE
118.82%
Debt / Equity
0.00
52W High
$620.59
52W Low
$277.23
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
D.E. Shaw
David Shaw
528K$296.68MNEW
Renaissance Technologies
Jim Simons (founder)
466K$261.68MNEW
Citadel
Ken Griffin
80K$45.07MNEW
Marshall Wace45K$25.25MNEW
Explore all tracked funds →
About Medpace Holdings, Inc.

Medpace Holdings is a global, full-service clinical contract research organization that provides outsourced drug development and clinical trial services to biotechnology, pharmaceutical, and medical device companies. The firm specializes in comprehensive clinical development support across phases I through IV, offering services including clinical trial management, regulatory affairs, patient recruitment and retention, data management, medical writing, pharmacovigilance, bioanalytical laboratory services, and imaging capabilities. Medpace serves small and midsize biopharmaceutical sponsors that lack internal capacity to conduct trials independently, as well as larger pharmaceutical firms seeking specialized expertise. Operating across North America, Europe, Asia, South America, Africa, and Australia, Medpace combines scientific expertise with operational excellence to accelerate drug development timelines. Founded in 1992 and headquartered in Cincinnati, Ohio, the company supports the global outsourcing environment for clinical research and development, helping sponsors navigate complex regulatory requirements and bring new therapeutics to market efficiently.

CEO
Dr. August James Troendle M.D.
Employees
6,200
Quick Facts
Exchange—
SectorHealthcare
IndustryDiagnostics & Research
Market Cap—
Avg Volume308.07K
Popular Stocks
AAPL
Apple Inc.
MSFT
Microsoft Corporation
NVDA
NVIDIA Corporation
AMZN
Amazon.com Inc.
GOOGL
Alphabet Inc. Class A
GOOG
Alphabet Inc. Class C
META
Meta Platforms Inc.
TSLA
Tesla Inc.
Key Dates

Earnings calendar coming soon. Subscribe to get notified when MEDP reports next.

Get earnings alerts →